
Alkem Labs stated that it continues to manufacture and supply approved products from the said facility to the US market, adding that there is no material impact on current operations, financial, or other activities of the company.
as of 21/11/2026, 11:20:57 am
02/Price history
Max · monthly candles. Hover the chart for the OHLC of any candle; the table below holds the same data row by row.
| 1 Nov 2026 | 5,100.00 | 5,475.00 | 5,044.00 | 5,185.00 | +1.67% | 431.00 | 27.62 L |
| 1 Oct 2026 | 5,150.00 | 5,407.00 | 4,811.00 | 5,113.50 | -0.71% | 596.00 | 25.83 L |
| 1 Sept 2026 | 5,329.50 | 5,466.50 | 5,051.00 | 5,163.50 | -3.11% | 415.50 | 31.94 L |
| 1 Aug 2026 | 5,774.50 | 5,774.50 | 5,175.00 | 5,329.50 | -7.71% | 599.50 | 27.24 L |
| 1 Jul 2026 | 5,594.00 | 5,882.50 | 5,487.00 | 5,751.50 | +2.82% | 395.50 | 34.95 L |
| 1 Jun 2026 | 5,443.50 | 5,608.00 | 5,162.50 | 5,570.00 | +2.32% | 445.50 | 31.00 L |
| 1 May 2026 | 5,382.00 | 5,789.00 | 5,313.00 | 5,498.00 | +2.16% | 476.00 | 28.49 L |
| 1 Apr 2026 | 5,320.50 | 5,735.00 | 5,075.00 | 5,400.00 | +1.49% | 660.00 | 26.41 L |
| 1 Mar 2026 | 5,415.00 | 5,665.00 | 5,111.50 | 5,299.00 | -2.14% | 553.50 | 21.83 L |
| 1 Feb 2026 | 5,690.00 | 5,915.00 | 5,328.50 | 5,639.50 | -0.89% | 586.50 | 28.90 L |
Historical price and volume data · Showing 1–10 of 132
03/Valuation & returns
Company value benchmarked against the sector median. The ratio set is sector specific — banks report NIM, CASA and Net NPA instead of EV/EBITDA.
Price ÷ earnings per share
Worse than sector by 166%
Price ÷ book value per share
Better than sector by 1%
Net income ÷ total assets
Better than sector by 663%
Net income ÷ shareholders' equity
Better than sector by 3578%
EBIT ÷ capital employed
Better than sector by 16%
Liquid assets ÷ current liabilities
Worse than sector by 61%
Enterprise value ÷ EBITDA
Better than sector by 23%
04/Business
Sector: Pharmaceuticals
Alkem Laboratories Ltd. is an India-based pharmaceutical company engaged in the development, manufacturing, and sale of pharmaceutical products. The Company operates in a single business segment-Pharmaceuticals. It produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it markets in India and international markets. It has a portfolio of approximately 800 brands in India and maintains a presence in over 40 international markets, with the United States being its key focus market. Its offerings include therapies, prescription (Rx) products, and Alkem generics. Its therapy offerings cover multiple medical fields, including anti-infectives, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory care, rheumatology, and urology. The Company’s subsidiaries include Ascend Laboratories (Pty) Ltd, Pharmacor Pty Limited, Alkem Laboratories Corporation, and others.
reported in crore
reported in billion
Market capitalisation is reported at the sector-constituent level, not the standalone company level.
05/Profit & loss
Annual figures in ₹ crore. Growth marked reported is provided; margins are derived.
| Revenue | 15,296 | 13,458 | 12,978 | 11,815 |
|---|---|---|---|---|
| Revenue growthreported | 13.7% | 3.7% | 9.8% | — |
| Operating profit | 2,871 | 2,527 | 2,023 | 1,305 |
| Operating profit growthreported | 13.6% | 24.9% | 55.1% | — |
| Operating marginderived | 18.8% | 18.8% | 15.6% | 11.0% |
| Net profit | 2,353 | 2,216 | 1,811 | 1,007 |
| Net profit growthreported | 6.2% | 22.3% | 79.9% | — |
| Net marginderived | 15.4% | 16.5% | 14.0% | 8.5% |
| EPS — basic₹/share, annual | 192.51 | 181.11 | 150.19 | 82.31 |
Figures in ₹ crore. Margin rows are computed from the reported values.
06/Balance sheet
Only annual balance sheets are available — the quarterly filter does not apply here. Figures in ₹ crore; net worth is assets minus liabilities.
| Total assets | 20,873 | 17,691 | 15,575 | 13,757 |
|---|---|---|---|---|
| Total liabilities | 6,524 | 5,257 | 4,861 | 4,322 |
| Net worthderived | 14,349 | 12,434 | 10,714 | 9,435 |
| Liabilities ÷ assetsderived | 31.3% | 29.7% | 31.2% | 31.4% |
| Asset growthderived | 18.0% | 13.6% | 13.2% | — |
Figures in ₹ crore. Stacked chart height equals total assets.
| Non-Current Assets | 8,662 | 6,880 | 5,163 | 5,027 |
|---|---|---|---|---|
| Current Assets | 12,211 | 10,811 | 10,412 | 8,730 |
| Total Assets | 20,873 | 17,691 | 15,575 | 13,757 |
| Current Liabilities | 4,783 | 3,961 | 3,995 | 3,707 |
| Net Current Asset | 7,428 | 6,851 | 6,417 | 5,023 |
| Non-Current Liabilities | 1,741 | 1,297 | 866 | 615 |
| Equity Capital | 14,349 | 12,434 | 10,714 | 9,435 |
| Total Equity & Liabilities | 20,873 | 17,691 | 15,575 | 13,757 |
Figures in ₹ crore unless the line item is per-share.
07/Cash flow
Annual only, in ₹ crore. Negative values are outflows, so healthy companies usually show positive operating and negative investing cash flow.
| Operating activities | 1,963 | 1,913 | 1,948 | 1,683 |
|---|---|---|---|---|
| Operating changereported | 2.6% | -1.8% | 15.8% | — |
| Investing activities | -1,667 | -1,299 | -1,008 | 113 |
| Investing changereported | -28.4% | -28.8% | -993.7% | — |
| Financing activities | -503 | -811 | -1,145 | -1,761 |
| Financing changereported | 37.9% | 29.2% | 35.0% | — |
| Net cash flowderived | -208 | -197 | -205 | 35 |
| Free cash flowoperating + investing | 296 | 614 | 940 | 1,795 |
Figures in ₹ crore.
| Profit before tax | 2,871 | 2,527 | 2,023 | 1,305 |
|---|---|---|---|---|
| Income before WC changes | 3,007 | 2,631 | 2,407 | 1,629 |
| Change in Assets | -664 | -455 | -430 | 262 |
| Change in Liabilities | 249 | 241 | 379 | 65 |
| Change in WC | -415 | -214 | -52 | 327 |
| Cash flow from Operations | 1,963 | 1,913 | 1,948 | 1,683 |
| Cash flow from Investing | -1,667 | -1,299 | -1,008 | 113 |
| Cash flow from Financing | -503 | -811 | -1,145 | -1,761 |
| Total Cash Flow | -208 | -197 | -205 | 35 |
| Cash (Start of the year) | -120 | 66 | 274 | 232 |
| Cash (End of the year) | -342 | -120 | 66 | 274 |
Figures in ₹ crore unless the line item is per-share.
09/Events
Dividends, bonuses, splits and rights issues. Filter by type, sort by any date, and expand a row for the full event detail.
| DividendFinal | ₹10.00 | 500.0% | 07 Aug 2026 | 07 Aug 2026 | 29 May 2026 | |
| DividendInterim | ₹43.00 | 2150.0% | 20 Feb 2026 | 20 Feb 2026 | 13 Feb 2026 |
10/Comparison
Competitor set priced live. Filter by sector, sort any column, and expand a peer for its business description.
| SUNPHARMASUN Pharmaceutical IND L | Pharmaceuticals | ₹1,884.90 | -0.79% | 19.16 L | ₹4,52,299 Cr | $50.26B | |
| DIVISLABDivi S Laboratories Ltd | Pharmaceuticals | ₹11,180.50 | +0.02% | 4.05 L | ₹2,97,325 Cr | $33.04B | |
| TORNTPHARMTorrent Pharmaceuticals L | Pharmaceuticals | ₹4,689.50 | +1.70% | 2.00 L | ₹1,78,727 Cr | $19.86B | |
| LAURUSLABSLaurus Labs Limited | Pharmaceuticals | ₹2,294.60 | -0.49% | 8.79 L | ₹1,24,002 Cr | $13.78B | |
| ZYDUSLIFEZydus Lifesciences Ltd | Pharmaceuticals | ₹1,200.00 | -0.24% | 7.80 L | ₹1,19,207 Cr | $13.25B | |
| DRREDDYDR. Reddy S Laboratories | Pharmaceuticals | ₹1,390.20 | -0.76% | 8.31 L | ₹1,16,145 Cr | $12.90B | |
| CIPLACipla Ltd | Pharmaceuticals | ₹1,415.00 | -0.25% | 14.84 L | ₹1,14,312 Cr | $12.70B | |
| MANKINDMankind Pharma Limited | Pharmaceuticals | ₹2,665.00 | +1.37% | 4.56 L | ₹1,09,870 Cr | $12.21B | |
| AUROPHARMAAurobindo Pharma Ltd | Pharmaceuticals | ₹1,799.00 | -0.37% | 8.11 L | ₹1,03,298 Cr | $11.48B | |
| LUPINLupin Limited | Pharmaceuticals | ₹2,014.00 | +0.76% | 6.31 L | ₹91,916 Cr | $10.21B |
Market cap is the sector-constituent figure reported per peer · Showing 1–10 of 10
11/Coverage
Articles published in the last seven days, paginated by the provider.

Alkem Labs stated that it continues to manufacture and supply approved products from the said facility to the US market, adding that there is no material impact on current operations, financial, or other activities of the company.

On Tuesday, venture capital firm Ribbit Capital’s investment entities, Ribbit Capital V and Ribbit Cayman GW Holdings V Ltd, sold a total of 8.7 crore shares of Groww for ₹1,905.3 crore.
Showing 1–2 of 2 articles
| Revenue | 14,712 | 12,965 | 12,668 | 11,599 |
|---|---|---|---|---|
| Other Income | 583 | 494 | 311 | 216 |
| Total Revenue | 15,296 | 13,458 | 12,978 | 11,815 |
| Total Expenses | 12,250 | 10,931 | 10,834 | 10,408 |
| Profit Before Tax | 2,871 | 2,527 | 2,023 | 1,305 |
| Tax | 518 | 311 | 212 | 298 |
| Profit After Tax | 2,353 | 2,216 | 1,811 | 1,007 |
| EPS - Basic | 192.51 | 181.11 | 150.19 | 82.31 |
| EPS - Diluted | 192.51 | 181.11 | 150.19 | 82.31 |
This breakdown is available annually, even when the summary above is quarterly. EPS rows are per share.